Margaret E. Huflejt

Margaret E. Huflejt

Auto-generated profile, based on publicly available information

Margaret E. Huflejt

Division of Thoracic Surgery and Thoracic Oncology, Department of Cardiothoracic Surgery, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 1989 in Photochemistry and Photobiology
Verified
Journal Article
Closed access
PDF file
JFJ. Fuchs
J. Fuchs
MHM. E. Huflejt
M. E. Huflejt
LRL. M. Rothfuss
L. M. Rothfuss
DWD. S. Wilson
D. S. Wilson
GCG. Carcamo
G. Carcamo
LPL. Packer
L. Packer

1 February 1998 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
TLT Lin
T Lin
TBT Brunner
T Brunner
BTB Tietz
B Tietz
JMJ Madsen
J Madsen
EBE Bonfoco
E Bonfoco
DGD R Green
D R Green
In vitro studies have demonstrated that intestinal intraepithelial lymphocytes (IEL) are constitutively cytotoxic; however, the mechanism and target of their cytotoxicity are unknown. Apoptosis of intestinal epithelial cells (IEC) and an increase in IEL numbers are classical signs of intestinal graft-versus-host disease (GVHD), although whether IEL can mediate IEC apoptosis directly in GVHD is unclear. Recent evidence suggests that target epithelial organ injury observed in GVHD is predominantly Fas-mediated; therefore, we investigated the possibility that IEL induce apoptosis of IEC through a Fas-mediated mechanism. Here, we demonstrate that the IEL isolated from normal mice readily display potent Fas ligand (FasL)-mediated killing activity after CD3 stimulation, and that IEC express Fas, suggesting that IEC are potential targets for FasL-mediated killing by IEL. In vitro, IEL isolated from GVHD mice have markedly increased FasL-mediated killing potential and are spontaneously cytolytic toward host-derived tumor cells predominantly through a Fas-mediated pathway. In vivo transfer of IEL isolated from GVHD mice induced significantly more IEC apoptosis in F1 wild-type mice than in Fas-defective F1lpr mice. Thus, these results demonstrate that FasL-mediated death of IEC by IEL is a major mechanism of IEC apoptosis seen in GVHD.

15 June 2001
Verified
Journal Article
Closed access
VGV V Glinsky
V V Glinsky
GGG V Glinsky
G V Glinsky
KRKate Rittenhouse-Olson
Kate Rittenhouse-Olson
MHM E Huflejt
M E Huflejt
OGO V Glinskii
O V Glinskii
TQT P Quinn
T P Quinn

1 February 1986 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
IFI.V. Fry
I.V. Fry
MHM. Huflejt
M. Huflejt
WEW.W.A. Erber
W.W.A. Erber
GPG.A. Peschek
G.A. Peschek
LPL. Packer
L. Packer

28 August 2014 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
FJFrancis Jacob
Francis Jacob
MAM Anugraham
M Anugraham
TPT Pochechueva
T Pochechueva
BTBrian Tse
Brian Tse
SAS Alam
S Alam
VHViola Heinzelmann-Schwarz
Viola Heinzelmann-Schwarz
Background: The level of plasma-derived naturally circulating anti-glycan antibodies (AGA) to P1 trisaccharide has previously been shown to significantly discriminate between ovarian cancer patients and healthy women. Here we aim to identify the Ig class that causes this discrimination, to identify on cancer cells the corresponding P1 antigen recognised by circulating anti-P1 antibodies and to shed light into the possible function of this glycosphingolipid. Methods: An independent Australian cohort was assessed for the presence of anti-P1 IgG and IgM class antibodies using suspension array. Monoclonal and human derived anti-glycan antibodies were verified using three independent glycan-based immunoassays and flow cytometry-based inhibition assay. The P1 antigen was detected by LC-MS/MS and flow cytometry. FACS-sorted cell lines were studied on the cellular migration by colorimetric assay and real-time measurement using xCELLigence system. Results: Here we show in a second independent cohort (n=155) that the discrimination of cancer patients is mediated by the IgM class of anti-P1 antibodies (P=0.0002). The presence of corresponding antigen P1 and structurally related epitopes in fresh tissue specimens and cultured cancer cells is demonstrated. We further link the antibody and antigen (P1) by showing that human naturally circulating and affinity-purified anti-P1 IgM isolated from patients ascites can bind to naturally expressed P1 on the cell surface of ovarian cancer cells. Cell-sorted IGROV1 was used to obtain two study subpopulations (P1-high, 66.1%; and P1-low, 33.3%) and observed that cells expressing high P1-levels migrate significantly faster than those with low P1-levels. Conclusions: This is the first report showing that P1 antigen, known to be expressed on erythrocytes only, is also present on ovarian cancer cells. This suggests that P1 is a novel tumour-associated carbohydrate antigen recognised by the immune system in patients and may have a role in cell migration. The clinical value of our data may be both diagnostic and prognostic; patients with low anti-P1 IgM antibodies present with a more aggressive phenotype and earlier relapse.

1 July 2008 in Blood
Verified
Journal Article
Closed access
PDF file
SLScot D. Liu
Scot D. Liu
CWChan C. Whiting
Chan C. Whiting
TTTamar Tomassian
Tamar Tomassian
MPMabel Pang
Mabel Pang
SBStephanie J. Bissel
Stephanie J. Bissel
MMM. Carrie Miceli
M. Carrie Miceli
During thymocyte development, the T-cell receptor (TCR) can discriminate major histocompatibility complex (MHC)/peptide ligands over a narrow range of affinities and translate subtle differences into functional fate decisions. How small differences in TCR input are translated into absolute differences in functional output is unclear. We examined the effects of galectin-1 ablation in the context of class-I–restricted thymocyte development. Galectin-1 expression opposed TCR partial agonist-driven positive selection, but promoted TCR agonist-driven negative selection of conventional CD8+ T cells. Galectin-1 expression also promoted TCR agonist-driven CD8αα intestinal intraepithelial lymphocytes (IEL) development. Recombinant galectin-1 enhanced TCR binding to agonist/MHC complexes and promoted a negative-selection-signaling signature, reflected in intensified rapid and transient extracellular signal-regulated kinase (ERK) activation. In contrast, galectin-1 expression antagonized ERK activity in thymocytes undergoing positive selection. We propose that galectin-1 aids in discriminating TCR-directed fate decisions by promoting TCR binding to agonist/MHC complexes and enforcing agonist-driven signals, while opposing partial-agonist signals. In this way, galectin-1 widens the distinction between TCR-directed functional fate cues.